Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and
cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease
(CKD) contribute to high CVD morbidity and mortality in this patient population.
Additionally, the traditional approaches towards the therapy of CVD have little impact on CV
mortality in these patients. Hydroxychloroquine (HCQ) used as anti-inflammatory in
rheumatological disorders, has multiple beneficial properties relevant to the process of
vascular disease. The effects of HCQ on atherosclerosis (AS) and vascular disease in CKD is
not known yet. Thus, the study hypothesis is that HCQ treatment in individuals with CKD will
provide clinically significant benefit in the management of CVD and will provide biological
and functional atherosclerotic benefits.